Adesto to Participate at the ROTH London Conference on June 18
Get Alerts IOTS Hot Sheet
Join SI Premium – FREE
SANTA CLARA, Calif., June 13, 2019 (GLOBE NEWSWIRE) -- Adesto® Technologies Corporation (NASDAQ: IOTS), a leading provider of innovative application-specific semiconductors and embedded systems for the IoT, today announced Narbeh Derhacobian, president and chief executive officer, will participate at the ROTH London Conference to be held at The InterContinental Park Lane Hotel in London, UK. Management will be available to meet with investors throughout the day on June 18th.
To schedule a meeting with management, please contact your ROTH representative.
About Adesto Technologies CorporationAdesto Technologies Corporation (NASDAQ: IOTS) is a leading provider of innovative application-specific semiconductors and embedded systems for the IoT. The company’s technology is used by more than 5,000 customers worldwide who are creating differentiated solutions across industrial, consumer, medical and communications markets. With its growing portfolio of high-value technologies, Adesto is helping its customers usher in the era of the Internet of Things. See: https://www.adestotech.com.
Follow Adesto on Twitter.
Adesto and the Adesto logo are trademarks or registered trademarks of Adesto Technologies Corporation or its subsidiaries in the United States and other countries. Other company, product, and service names may be trademarks or service marks of others.
Adesto Media Contact:Jen Bernier-Santarini+1 650-336-4222[email protected]
Adesto Investor Relations:Leanne K. SieversShelton Group[email protected]
Source: Adesto Technologies CorporationSerious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Narravero Named a Market Shaper in the 2026 Gartner® Emerging Market Quadrant for Digital Product Passport
- Vaultik Collaborates with Chubb to Connect AI-Powered Watch and Jewellery , Valuation to Insurance
- BioNxt Advances Cladribine Clinical Program with Completion of the Investigational Medicinal Product Dossier (IMPD) Ahead of Human Clinical Studies
Create E-mail Alert Related Categories
Press ReleasesRelated Entities
TwitterSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share